SUN VALLEY, CA--(Marketwired - April 17, 2014) - MultiCorp International, Inc. (PINKSHEETS: MCIC) has engaged Dr. Greg Maguire of BioRegenerative Sciences, Inc., along with Dr. Valentin Isacescu of North County Clinical Research, to work with the company to develop a clear path to begin clinical trials on their patented migraine medicine for eventual approval by the FDA.
The company released the following statement, "We're extremely excited to have such a qualified and experienced group to assist the company in mapping out a clear strategy for the migraine medication to gain approval from the FDA. While we understand this could be a long process, having a group that is so well versed on the proper procedures clinical trials require to gain approval, we feel we've chosen the perfect group to accomplish this portion of the process in the most expeditious manner possible. Once the report is completed in the next four to six weeks, the company will have a clear understanding as to the requirements from the FDA on beginning clinical trials," stated Mr. Paul D. Lisenby, CEO of MultiCorp International, Inc. Mr. Lisenby added, "We feel this medication could become a major player in the $3.2 billion dollar segment of the migraine pharmaceutical vertical."
Dr. Greg Maguire, CEO of BioRegenerative Sciences, Inc., stated, "Our group is very excited to help bring this important new drug candidate for migraines through the FDA 505(b)(2) NDA approval process." Dr Valentin Isacescu added, "Migraine is such a debilitating disorder for so many patients and a tremendous need exists for a medication to prevent and control this malady."
About MultiCorp International, Inc.
MultiCorp International, Inc. is a diverse company that operates in various business sectors that show true growth potential. The company builds on its executives experience in property development, constructions, medical, hospitality, agribusiness, commodities such as oil and gas, and entertainment. The company looks to expand through acquisitions of solid business models and management that have the potential to grow exponentially. The company will have additional subsidiaries that will eventually grow into being their own public entity, be sold, or continue to operate within MultiCorp. For further information please contact them at firstname.lastname@example.org
About BioRegenerative Sciences, Inc.
BioRegenerative Sciences, Inc. is a privately held corporation headquartered in San Diego, CA and currently has fifteen patent pending products on the market and is further developing a portfolio of therapeutic and cosmeceutical products and services based on BRS's core stem cell-based S2RM® Technology. For more information, please email: email@example.com, or call BRS at 858. 521.9203.
About North County Clinical Research
North County Clinical Research (NCCR) is a dedicated clinical research site located in the North County of San Diego. We specialize in central nervous system (CNS) indications, some medical indications, drug dependence, alcohol dependence, nicotine dependence, sleep disorders, and chronic pain clinical trials. We are comprised of physicians and research staff with over 20 years of combined experience conducting phase II through phase IV clinical trials. Our site is affiliated with Aurora Behavioral Health Care which provides excellent opportunities for recruitment and inpatient clinical trials.
For more information, please visit their website at http://www.nccresearch.com/
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.